Cargando…
Assessing provider and racial/ethnic variation in response to the FDA antidepressant box warning
INTRODUCTION: After the 2004 FDA box warning raised concerns about increased suicidal ideation among youth taking antidepressants, antidepressant use decreased for White youth but slightly increased for Black and Latino youth. Better understanding of patient and provider factors contributing to thes...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6341210/ https://www.ncbi.nlm.nih.gov/pubmed/30666633 http://dx.doi.org/10.1111/1475-6773.13104 |
_version_ | 1783388916462649344 |
---|---|
author | Cook, Benjamin L. Wang, Ye Sonik, Rajan Busch, Susan Carson, Nicholas Progovac, Ana M. Zaslavsky, Alan M. |
author_facet | Cook, Benjamin L. Wang, Ye Sonik, Rajan Busch, Susan Carson, Nicholas Progovac, Ana M. Zaslavsky, Alan M. |
author_sort | Cook, Benjamin L. |
collection | PubMed |
description | INTRODUCTION: After the 2004 FDA box warning raised concerns about increased suicidal ideation among youth taking antidepressants, antidepressant use decreased for White youth but slightly increased for Black and Latino youth. Better understanding of patient and provider factors contributing to these differences is needed to improve future risk warning dissemination. METHODS: We analyzed antidepressant prescriptions for youth aged 5‐17 in 2002‐2006 Medicaid claims data from four states (CA, FL, NC, and NY). In multilevel models, we assessed provider‐ and patient‐level contributions to changes in antidepressant use by race/ethnicity and compared responses to the box warning between providers with large (>2/3) and small (<1/3) proportions of minority patients. RESULTS: A significant amount of variance in overall prescribing patterns (calculated by the ICC) was explained at the provider level. Significant provider‐level variation was also identified in the differential effect of the box warning by racial/ethnic group. In a test of the influence of provider panel mix, we found that providers with large proportions of minority patients reduced antidepressant prescribing more slowly after the box warning than other providers. DISCUSSION: This study is the first to assess provider‐ and patient‐level variation in the impact of a health care policy change on treatment disparities. Black and Latino youth Medicaid beneficiaries were seen by largely different providers than their White counterparts, and these distinct providers were influential in driving antidepressant prescription patterns following the box warning. Concerted outreach to providers of minority beneficiaries is needed to ensure that risk warnings and clinical innovations diffuse swiftly across racial/ethnic minority groups. |
format | Online Article Text |
id | pubmed-6341210 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-63412102020-02-01 Assessing provider and racial/ethnic variation in response to the FDA antidepressant box warning Cook, Benjamin L. Wang, Ye Sonik, Rajan Busch, Susan Carson, Nicholas Progovac, Ana M. Zaslavsky, Alan M. Health Serv Res Health Equity INTRODUCTION: After the 2004 FDA box warning raised concerns about increased suicidal ideation among youth taking antidepressants, antidepressant use decreased for White youth but slightly increased for Black and Latino youth. Better understanding of patient and provider factors contributing to these differences is needed to improve future risk warning dissemination. METHODS: We analyzed antidepressant prescriptions for youth aged 5‐17 in 2002‐2006 Medicaid claims data from four states (CA, FL, NC, and NY). In multilevel models, we assessed provider‐ and patient‐level contributions to changes in antidepressant use by race/ethnicity and compared responses to the box warning between providers with large (>2/3) and small (<1/3) proportions of minority patients. RESULTS: A significant amount of variance in overall prescribing patterns (calculated by the ICC) was explained at the provider level. Significant provider‐level variation was also identified in the differential effect of the box warning by racial/ethnic group. In a test of the influence of provider panel mix, we found that providers with large proportions of minority patients reduced antidepressant prescribing more slowly after the box warning than other providers. DISCUSSION: This study is the first to assess provider‐ and patient‐level variation in the impact of a health care policy change on treatment disparities. Black and Latino youth Medicaid beneficiaries were seen by largely different providers than their White counterparts, and these distinct providers were influential in driving antidepressant prescription patterns following the box warning. Concerted outreach to providers of minority beneficiaries is needed to ensure that risk warnings and clinical innovations diffuse swiftly across racial/ethnic minority groups. John Wiley and Sons Inc. 2019-01-21 2019-02 /pmc/articles/PMC6341210/ /pubmed/30666633 http://dx.doi.org/10.1111/1475-6773.13104 Text en © 2019 The Authors. Health Services Research published by Wiley Periodicals, Inc. on behalf of Health Research and Educational Trust This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Health Equity Cook, Benjamin L. Wang, Ye Sonik, Rajan Busch, Susan Carson, Nicholas Progovac, Ana M. Zaslavsky, Alan M. Assessing provider and racial/ethnic variation in response to the FDA antidepressant box warning |
title | Assessing provider and racial/ethnic variation in response to the FDA antidepressant box warning |
title_full | Assessing provider and racial/ethnic variation in response to the FDA antidepressant box warning |
title_fullStr | Assessing provider and racial/ethnic variation in response to the FDA antidepressant box warning |
title_full_unstemmed | Assessing provider and racial/ethnic variation in response to the FDA antidepressant box warning |
title_short | Assessing provider and racial/ethnic variation in response to the FDA antidepressant box warning |
title_sort | assessing provider and racial/ethnic variation in response to the fda antidepressant box warning |
topic | Health Equity |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6341210/ https://www.ncbi.nlm.nih.gov/pubmed/30666633 http://dx.doi.org/10.1111/1475-6773.13104 |
work_keys_str_mv | AT cookbenjaminl assessingproviderandracialethnicvariationinresponsetothefdaantidepressantboxwarning AT wangye assessingproviderandracialethnicvariationinresponsetothefdaantidepressantboxwarning AT sonikrajan assessingproviderandracialethnicvariationinresponsetothefdaantidepressantboxwarning AT buschsusan assessingproviderandracialethnicvariationinresponsetothefdaantidepressantboxwarning AT carsonnicholas assessingproviderandracialethnicvariationinresponsetothefdaantidepressantboxwarning AT progovacanam assessingproviderandracialethnicvariationinresponsetothefdaantidepressantboxwarning AT zaslavskyalanm assessingproviderandracialethnicvariationinresponsetothefdaantidepressantboxwarning |